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RESEARCH ARTICLE
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ABSTRACT
Retinal gene delivery via intravitreal injection is hampered by various physiological barriers present in
the eye of which the vitreoretinal (VR) interface represents the most serious hurdle. In this study, we
present a retinal explant model especially designed to study the role of this interface as a barrier for
the penetration of vectors into the retina. In contrast to all existing explant models, the developed
model is bovine-derived and more importantly, keeps the vitreous attached to the retina at all times
to guarantee an intact VR interface. After ex vivo intravitreal injection into the living retinal explant, the
route of fluorescent carriers across the VR interface can be tracked. By applying two different imaging
methods on this model, we discovered that the transfer through the VR barrier is size-dependent since
40nm polystyrene particles are more easily taken up in the retina than 100 and 200 nm sized particles.
In addition, we found that removing the vitreous, as commonly done for culture of conventional
explants, leads to an overestimation of particle uptake, and conclude that the ultimate barrier to over-
come for retinal uptake is undoubtedly the inner limiting membrane. Damaging this matrix resulted in
a massive increase in particle transfer into the retina. In conclusion, we have developed a highly rele-
vant ex vivo model that maximally mimics the human in vivo physiology which can be applied as a
representative test set-up to assess the potential of promising drug delivery carriers to cross the VR
interface.
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1. Introduction
Today, blindness affects 180 million people worldwide. Next
to the tragic impact of vision loss on the lives and the sur-
roundings of these people, the health care costs associated
with blindness are immense (International AMD Alliance,
2010). Since many blinding pathologies find their origin in
the retina, a vast amount of research in academics and indus-
try is dedicated to the delivery of therapeutic entities (e.g.
steroids, antibodies, or nucleic acids) to the back of the eye.
For mutation-dependent pathologies, gene therapy has made
a great leap forward over the last decade. As leading
example, treatment of RPE65-dependent Leber congenital
amaurosis (LCA) by subretinal injection of adeno-associated
viral vectors (AAV) has shown promising results in Phase 3
clinical trials and is expected to reach the clinic soon
(Schimmer & Breazzano, 2015; Spark Therapeutics Press
Release, 2016). However, subretinal injections are mainly effi-
cient to reach cells surrounding the injection spot, i.e. photo-
receptors or RPE cells. Hence, the majority of retinal gene
therapy trials are focused on treatment of the outer retina.
Nevertheless, the inner retina harbors important target cells
as well including retinal ganglion cells (RGCs) as target for
Leber Hereditary Optic Neuropathy (LHON) (Boye et al.,
2013), M€uller cells for neurotrophic strategies (Gauthier et al.,
2005), and bipolar and amacrine cells for optogenetic therapy
(Busskamp et al., 2012). It is, however, not at all evident to
reach these cell types via subretinal injection.
An alternative method to reach the inner retina is intravi-
treal (IVT) injection, a technique that is considered safe, min-
imally invasive and relatively easy to perform (Englander
et al., 2013). Nonetheless, the transfer of (high molecular
weight) drugs and nanosized particles carrying drugs into the
retina after IVT injection remains troublesome, primarily
because of the presence of the vitreoretinal (VR) interface. As
shown in Figure 1, this interface consists of three structures:
peripheral vitreous, the inner limiting membrane (ILM), and
M€uller cell endfeet. The vitreous, a transparent gel composed
of collagen fibrils filled up with hyaluronic acid, may hamper
the mobility of carriers preventing them to reach the retina
(Peeters et al., 2005; Le Goff & Bishop, 2008; Da Costa et al.,
2016). The ILM has an extracellular matrix structure com-
posed of a collagen IV network intertwined with proteogly-
cans, laminin, and fibronectin (Halfter et al., 2008; Bu et al.,
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2015). It represents a physical border between the vitreous
and the retina and functions as a sieve that more than often
impedes the transfer of drug carriers into the retina (Pitk€anen
et al., 2004; Koo et al., 2012; Gan et al., 2013). Once drug car-
riers pass the vitreous and ILM they encounter retinal cells,
where the first cell type they face is likely the M€uller cell, a
glial cell of which the endfeet align with the ILM. If these ret-
inal cells efficiently internalize the drug carriers, retinal deliv-
ery can finally be regarded as successful.
Aiming for the delivery of nucleic acids in retinal cells, sev-
eral groups have reported successful penetration of both
non-viral as well as viral gene carriers through the entire VR
interface of rodents, resulting in gene expression in the ret-
ina. In animals larger than rodents, however, IVT injection
rarely results in effective gene expression (Pitk€anen et al.,
2004; Hellstr€om et al., 2009; Koo et al., 2012; Mowat et al.,
2014; Boyd et al., 2016; Takahashi et al., 2017). Interspecies
differences greatly hamper the extrapolation of successful IVT
therapies in rodents to larger animal models and humans.
This is likely because the VR interface is substantially more
difficult to overcome in larger species (Trapani et al., 2015).
Indeed, the anatomy of the rodent eye and the structure of
its vitreous and ILM is less representative for human physi-
ology (Xu et al., 2013; The Lasker/IRRF Initiative for
Innovation in Vision Science, 2014). As an example, the thick-
ness of the mouse ILM is estimated to be around 100 nm,
while a parafoveal thickness of up to 4 mm is measured in
human eyes (Henrich et al., 2012; Halfter et al., 2015). In light
of this, some research groups perform drug delivery studies
directly on explants of larger species (Kobuch et al., 2008;
Fradot et al., 2011). Nevertheless, in these studies the vitre-
ous is separated from the retina so that information regard-
ing the VR interface is lost. Therefore, there is an urgent
need for models with an intact VR interface based on larger
animals since it is expected these will be more representative
for the human VR interface. Such models will become highly
useful in research which aims for drug delivery into the
retina.
To address this need, we developed an ex vivo explant
model that is bovine-derived and most importantly, guaran-
tees an intact VR interface by keeping the vitreous attached
to the retina at all times. Drugs or drug carriers can be
injected ex vivo into the vitreous of the VR explant after
which their potential to cross the VR interface as well as their
transport route into the retina can be examined by
microscopy. In this paper, we present the methodology of
this novel VR explant and validate its retinal morphology and
viability. Furthermore, we demonstrate the potential of the
model in drug delivery research by studying how the size of
nanosized polystyrene beads (as a model for nanoparticles
carrying drugs) influences their transport over the VR inter-
face. Finally, we apply the presented model to draw conclu-
sions on the drug delivery barrier role of the separate parts
of the VR interface.
2. Methods
2.1. Materials
Carboxylated polystyrene beads (FluoSpheresVR ) were pur-
chased from Molecular ProbesTM: 40 nm (8795), 100 nm
(F8800), 200 nm (F8809). Dyes for M€uller cell and viability
staining were obtained from Invitrogen: Hoechst 33342
(H3570), FMVR 1-43 (T3163), MitotrackerVR Deep Red (M22426),
Propidium iodide (P3566). Antibodies against glutamine syn-
thetase (ab73593) and Collagen IV (ab6586) were purchased
from Abcam; AlexaFluorVR 647 tagged secondary antibody
(A27040) was obtained from Invitrogen. Cell culture materials
were mostly acquired from GibcoTM: CO2 Independent
medium (18045088), NeurobasalVR -A medium (10888022),
Advanced DMEM medium (12491023), B-27VR supplement
(17504044), Penicillin–streptomycin (15140122), L-Glutamine
(25030081), Trypsin–EDTA 0.25% (25200072).
2.2. Nanoparticle characterization
The hydrodynamic size and zeta potential of the
FluoSpheresVR are determined using a Malvern Zetasizer Nano
(Malvern Instruments, Worcestershire, U.K.). For this purpose,
the FluoSpheresVR are diluted a thousand times in HEPES buf-
fer (25mM, pH 7.2) prior to performing the measurements at
25 C. Size measurements are done in triplicate with three
runs per replicate, and presented based on the number dis-
tribution. The zeta potentials are calculated from the electro-
phoretic mobility of the FluoSpheres based on the Henry
equation considering the Smoluchowski approximation. Zeta
potential measurements are done in triplicate with two runs
per replicate.
2.3. Dissection and culture of a conventional retinal
explant
Fresh bovine eyes are obtained from the local slaughter-
house where they are enucleated up to 15min after the ani-
mal is sacrificed. The eyes are transported and kept in ice
cold CO2 independent medium until dissection. After remov-
ing all extra-ocular connective tissue and disinfecting the
eyes by soaking them in 20% ethanol, the sclera is punctured
with a 21G needle around 10mm below the limbus. This
hole next serves as an entry point for the scissors used to
bisect the eye. After bisection the eye, the vitreous is
removed and the posterior eye cup is filled with cold CO2
independent medium. Next, 3–4 flaps are cut in the eyecup,
Figure 1. Schematic drawing of the vitreoretinal interface. G: Ganglion cell;
ILM: inner limiting membrane; M: M€uller cell; N: nerve fiber; VR: vitreoretinal.
DRUG DELIVERY 1385
D
ow
nl
oa
de
d 
by
 [G
he
nt 
Un
ive
rsi
ty 
Li
br
ary
] a
t 2
2:4
7 1
9 S
ep
tem
be
r 2
01
7 
preferably along large veins. While the whole structure is
submerged in medium, a trephine blade (BeaverVR ) with
10mm diameter is used to isolate a circular piece of retina
from each flap. The explant is then removed from the eyecup
by gently pipetting medium below. Two of these explants
are then placed on a dry 75mm TranswellVR explant filter
after which the explant filter is moistened with explant cul-
ture medium (NeurobasalVR -A, 1% B-27VR supplement, 1%
Penicillin–streptomycin, 0.5% L-glutamine) and 10ml of the
same medium is added below the explant filter. Finally, the
explants are incubated at 37 C and 5% CO2.
2.4. Dissection and culture of a vitreoretinal explant
Our newly developed dissection protocol differs from the
conventional one by the preservation of vitreous and an
intact ILM during dissection. The preparation of this so-
called ‘vitreoretinal explant’ is shown in Figure 2(A). Before
dissection, isolated bovine eyes are gently warmed by
20–30minutes incubation in CO2 independent medium at
room temperature, a crucial step to allow smooth separation
of the retina from the RPE-choroid layer in step E of the
protocol. As for conventional explants, the sclera is punc-
tured with a 21G needle around 10mm below the limbus
(step A). In step b, the eye is bisected so that a posterior
eye cup filled with vitreous gel remains. Next, at the rim of
the eyecup, the retina is gently detached from the choroid
using a fine pincet, except at the side of the optic nerve
(step C). Then, the vitreous is gently pulled down during
which the attached retina slides along (step D–E). After cut-
ting the optic nerve (step f), the whole tissue is slid with
vitreous side upwards into a culture dish of 10 cm (Corning)
filled with cold CO2 independent medium. In step g, a scal-
pel is used to cut up to three pieces of VR explant (up to
1.5 cm2) from the vitreous side downwards through the ret-
ina. Hereby the potentially damaged edges of the retinal tis-
sue are avoided. In step I–K, a plastic Pasteur pipette with a
cut tip is used to gently aspire the VR explant and to trans-
fer it to a dry explant filter from a 75mm TranswellVR dish
(3419, Corning). Excess amounts of vitreous (e.g. lying next
to the retina) can then be removed by aspiration of some
vitreous using a plastic Pasteur pipette while cutting
through the gel with scissors. Finally, 10ml of supplemented
NeurobasalVR -A medium is added below the explant filter
(Step L), and the VR explant is placed in an incubator with
5% CO2 at 37 C.
2.5. Ex vivo injection of nanomaterials
Immediately after explant dissection, carboxylated PS beads
(1.421015 nanoparticles/ml) were injected (using a 30G nee-
dle) in the vitreous layer covering the retina. Multiple injec-
tions (about 50 mL per injection) within one VR explant were
performed. The injections were done ‘horizontally’ to avoid
direct transfer of nanoparticles into the retina (Figure 2(A),
M). As shown in step N, each intravitreal injection typically
resulted in an ‘injection band’ (arrows) containing a high con-
centration of (fluorescent) beads. Following injection, the
beads then diffuse through the vitreous toward the retina.
Since IVT injection is not possible in conventional retinal
explants (as there is no remaining vitreous), 25 ml of the car-
boxylated PS beads was applied on top of the explants. All
Figure 2. (A) Step-by-step overview of the dissection protocol to culture a bovine vitreoretinal explant. (B) set-up for ‘direct imaging’ of the vitreoretinal explant.
(C) Workflow applied for cryosectioning of the retina and cryosection imaging.
1386 K. PEYNSHAERT ET AL.
D
ow
nl
oa
de
d 
by
 [G
he
nt 
Un
ive
rsi
ty 
Li
br
ary
] a
t 2
2:4
7 1
9 S
ep
tem
be
r 2
01
7 
explants were incubated with the PS beads at 37 C for
24 hours.
2.6. Explant staining, fixation and ‘direct imaging’
Explants were stained by the injection of a mixture of dyes
in the vitreous covering the retina, followed by an incubation
at 37 C for 2 hours. Nuclei were stained with 10 mg/ml
Hoechst, lipid membranes with 20 mg/ml FM-43 and M€uller
cells with 2mM Mitotracker Deep red following the protocol
of Uckermann et al. (2004). To evaluate retinal cell viability, a
mixture of Propidium Iodide and Hoechst was added to the
explant culture medium below the explant filter resulting in
a final concentration of 10 mg/ml for both dyes. After dye
incubation, the explants were fixed by replacing the explant
culture medium with 4% paraformaldehyde (in PBS) during
2 hours at 4 C. After fixation, the fixative was replaced by
PBS for imaging.
Fixed ex vivo explants were imaged with a confocal micro-
scope (C1-si, Nikon) directly or after preparing cryosections
(see below). For ‘direct imaging’, a 60 water dipping object-
ive (NIR, Apo) with a large working distance (2.8mm) was
pushed on top of the vitreous which allowed to image from
the vitreous until the ganglion cell layer (Figure 2(B)).
2.7. Explant cryosectioning and immunohistochemistry
After fixation, the fixative below the explant filter is removed
and replaced by 30% sucrose and incubated overnight at
4 C. After snap freezing the samples in Tissue-TekVR O.C.T.
(Sakura) with liquid nitrogen, 14 mm sections were cut with a
cryostat (Leica). For reliability of our results, we applied the
workflow drawn in Figure 2(C): 16 sections were analyzed per
retina, resulting from 4 distinct retina locations. These retinal
sections were permeabilized with 0.1% Triton for 5min prior
to a 1 hour incubation at room temperature with 5% goat
serum in PBS as a blocking step. Next, sections were incu-
bated overnight at 4 C with 1:200 rabbit antibody against
Collagen IV. Finally, after a 1 hour incubation at room tem-
perature with goat anti-rabbit Alexafluor 647 conjugated sec-
ondary antibody and 10 mg/ml Hoechst the sections were
mounted with Vectashield (Vector Laboratories) and prepared
for imaging. The ‘cryosection imaging’ was done with a con-
focal microscope (C1-si, Nikon) using a 10 objective (CFI
Plan Apochromat, Nikon) and a 60 water objective (NIR
Apo, Nikon).
2.8. Uptake of nanoparticles by the retina: cryosection
image processing for semi-quantitative analysis
To analyze the uptake of the PS beads by the retina, follow-
ing the workflow presented in Figure 2(C), (minimally) two
images were taken per retinal section, resulting in at least 32
images per retinal explant. Image analysis was done with FIJI
(NIH) as follows: using the Polygon Tool, a region of interest
(ROI) was drawn around the retinal area below the ILM.
Then, the area outside this ROI, i.e. above the ILM, was col-
ored black using the ‘clear tool’ so only particles present
within the ROI (retina) would be counted. The number of
particles within the ROI was counted using the ‘analyze parti-
cles’ tool. Finally, the surface area of the ROI was measured
by applying the ‘measure’ tool in the ROI manager so that
the number of counted particles could be recalculated per
1000 mm2. Based on these results, the various sections were
categorized in three categories i.e. samples containing a low
(<10), higher (10–30) or very high (>30) amount of particles
per 1000 mm2.
3. Results
3.1. Vitreoretinal explant morphology and viability
VR explant differs from the conventional explant by the pres-
ence of an intact VR interface (e.g. vitreous and ILM). Despite
this seemingly small difference, the search for a dissection
protocol suitable to obtain the VR explant was intensive. The
dissection protocol as presented in Figure 2(A) resulted in an
explant that keeps a layer of vitreous attached to the retina.
Next, we visualized the ganglion cell layer (GCL) and nerve
fiber layer (NFL) of the VR explant by staining for M€uller cells
and lipid membranes. Figure 3(A) shows that a large portion
of this layer is taken in by a patchwork of M€uller cell endfeet
(red color) separated by lipid membranes (green color).
Nerve fibers run unidirectional through these patchworks,
while other dye-less cell types such as RGCs are randomly
scattered within this layer.
When we compare the morphology of the bovine GCL/
NFL layer with the morphology of Mitotracker-stained tissue
of others species as presented in literature (Figure 3(B)), the
morphology of the bovine GCL/NFL layer highly relates to
that of the human retina. Interestingly, also bovine vitreous
has a similar structure as human vitreous and has therefore
been frequently applied in ex vivo models developed for IVT
drug delivery studies (Xu et al., 2000, 2013; Peeters et al.,
Figure 3. (A) Confocal view on the GCL/NFL layer as obtained through ‘direct imaging’. M€uller cells (red) are stained with Mitotracker Deep Red, lipid membranes
and nerve fibers (green) with FM-43. Scale bar: 20 mm. (B) Confocal view onto the GCL/NFL layer of different species stained for M€uller cells. Bovine retinal tissue
was stained by Mitotracker Deep Red (own data); examples of human, rat and rabbit tissue were stained by Mitotracker Orange and taken from (Uckermann et al.,
2004).
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2005; Martens et al., 2013; K€asdorf et al., 2015). Therefore,
both the presence of vitreous and the representative GCL/
NFL layer in the bovine-derived VR explant is highly likely of
relevance for drug delivery studies in human.
Next, we aimed to assess if the dissection protocol and
explant culture conditions maintain the integrity and viability
of the various retinal layers. VR explants were stained with
the nuclear label Hoechst to identify the various layers and
check gross retinal morphology. Also, the cell-impermeable
(red) dye Propidium Iodide (PI) was added to identify cell via-
bility. The cryosections in Figure 4 show that the architecture
of the retina is nicely preserved and all retinal layers can be
easily distinguished. In addition, a layer of vitreous gel is
clearly attached at the side of the ILM as indicated by the
arrows. Also note that the number of PI-positive cells is very
limited at both time points from which we conclude that the
explant is viable for at least 48 hours.
3.2. Influence of nanoparticle size on the transfer
through the vitreoretinal interface studied by direct
imaging of the VR explant
Following the successful characterization of the morphology
and viability of the VR explant, we applied the model to
study, for the first time, the size-dependent penetration of
polystyrene (PS) beads over the intact VR interface of a large
animal. The three selected sizes of the PS beads correlate
with the sizes of (intravitreally injected) gene carriers cur-
rently under investigation for the treatment of retinal dis-
eases, while 40 nm ranges at the upper size limit of viral
vectors, the 100 and 200 nm sized beads represent the size
of most common non-viral vectors. Table 1 represents the
size and zeta-potential (a measure for the surface charge) of
the carboxylated PS beads dispersed in HEPES buffer, as
measured by DLS. As expected, the particle sizes were highly
reproducible and all particles were negatively charged due to
the carboxylated surface. This negative charge is of import-
ance since negatively charged entities are known to diffuse
well through the vitreous, increasing their potential to reach
the retina.
As described above, the PS beads were administered into
the VR explant by multiple 50 ml ex vivo IVT injections.
24 Hours post-injection, the transfer of the NPs from the vit-
reous into the retina was investigated using the direct imag-
ing method. Here, a water dipping objective is gently pushed
on top of the vitreous to image the vitreous and NFL/GCL
layer (Figure 2(A)). Figure 5(A) shows the transfer of green PS
beads through the VR interface into the NFL/GCL layer (of
which the M€uller cell endfeet are stained in red).
Our data show that only 40 nm particles can be spotted in
the retina, while 100 nm and 200 nm NPs do not appear in
the NFL/GCL layer. Note that, on the micro-scale, the position
of the retina as it occurs in Figure 3 is not entirely flat.
Therefore, often images were obtained in which the vitreous
(right top side) appears bright green as it is heavily loaded
with green PS beads, while the rest of the image displays
M€uller cell endfeet and nerve fibers. Remarkably, 40 nm par-
ticles that were able of crossing the VR interface tended to
selectively co-localize with the Mitotracker-stained M€uller
cells. Indeed, 40 nm PS beads were only present in the
mosaic of red islands representing M€uller cells, though not in
the blood vessels, nerve fibers or dye-less cells representing
other retinal cell types (Figure 5(B)).
Figure 4. Cryosection imaging showing gross morphology and tissue viability of vitreoretinal explants. Nuclei are stained with Hoechst (blue), dead cells are stained
with propidium iodide (red). Arrows indicate the vitreous layer. Scale bar: 100 mm.
Table 1. Size and zeta-potential of the carboxylated PS beads in HEPES
buffer.
Size (nm) Zeta potential (mV)
40 nm 37 (±0.4) 14 (±0.4)
100 nm 90 (±0.4) 30 (±0.8)
200 nm 205 (±1.2) 39 (±0.4)
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3.3. Influence of nanoparticle size on the transfer
through the vitreoretinal interface studied by
cryosection imaging of the VR explant
We further investigated the uptake of differently sized PS
beads in the VR explant by cryosection imaging (Figure 2(C)).
Considering our interest in the VR interface, we visualized
the ILM by staining it with (red) antibodies against Collagen
IV. Typically this resulted in images as presented in
Figure 6(B), where the vitreous, which appears as bright
green due to the high number of PS beads, nicely aligns
with the intact ILM. Based on these images, we estimated
the thickness of the ILM to be around 2mm, which correlates
well with the average thickness of fixed human ILM (2mm)
reported before (Halfter et al., 2015).
To rule out any bias, cryosection preparation was per-
formed complying with the workflow drawn in Figure 2(C)
Figure 5. Transfer of (green) PS beads through the VR interface, as visualized by ‘direct imaging’ (Figure 2B). M€uller cells (red) are stained with Mitotracker Deep
Red, cell nuclei (blue) with Hoechst. (A) 40 nm particles enter the M€uller cells, 100 and 200 nm particles remain in the vitreous (indicated with ‘V’). Scale bar: 25 mm.
For optimal contrast we refer the reader to the online version. (B) Co-localization of 40 nm PS beads (green) with M€uller cells. Asterisks () indicate blood vessels,
number signs (#) indicate nerve fibers. Scale bar: 25 mm.
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followed by image processing, resulting in at least 32 images
that were analyzed per given NP size. We opted for this sys-
tematic and objective approach based on the initial observa-
tion that NP uptake often greatly varied between different
explants and even between different locations within one
explant. Figure 6(A) shows the number of NPs that pene-
trated in the retina, subdivided in categories of low (<10
NPs), intermediate (10–30 NPs), and high (>30 NPs) penetra-
tion per 1000 mm2 of retina. The size-dependent uptake of
the PS beads confirms the trend observed in Figure 5(A).
Indeed, the majority of sections originating from explants
incubated with 40 nm NPs contain a large amount of beads
inside the retina (Figure 6(C), black bar) while the opposite is
true for the 100 and 200 nm sized NPs. Figure 6(B) shows
representative images of respectively high (>30 NPs/1000
mm2 as seen with 40 nm NPs), low (10–30 NPs/1000 mm2 as
observed with 100 nm NPs) and medium (<10 NPs/1000 mm2
for 200 nm NPs). Also on these images, the high VR transfer
into the retina of 40 nm beads in comparison with the larger
particles is clearly noticeable.
3.4. Relevance of vitreous and inner limiting membrane
as drug delivery barriers
To illustrate the importance of an ex vivo model that keeps
the entire VR interface intact, we have compared the trans-
port of 100 nm sized PS beads into the retina using respect-
ively our VR explants and conventional explants without
vitreous. As can be derived from Figure 7(B), the transfer of
particles into the retina observed using conventional explants
was clearly higher. In fact, the fraction of sections con-
taining>30 NPs per 1000 mm2 nearly tripled (11–31%). We
furthermore observed that absence of vitreous allowed larger
particle aggregates to enter the retina (Figure 7(A) – vitre-
ous). In view of these observations, it is evident that tearing
off the vitreous significantly affects the transport of NPs into
the retina which may result in an inaccurate estimation of
the potential of NPs to cross the VR interface. To further
explore to which extent the ILM is a transport barrier for NPs,
we purposely sought for spots in the retinal sections with a
compromised ILM. It has indeed been reported before that
the ILM can be severely damaged by tearing of the vitreous
(Russell, 2012). A typical image of this case is shown in
Figure 7(A) (-ILM) where the ILM is absent in the center of
the image, a condition which clearly results in unusually high
NP transport.
4. Discussion
Intravitreal injection is globally a daily employed administra-
tion technique for the delivery of small therapeutics to the
retina, such as anti-VEGF medication or antibiotics. For the
delivery of gene carriers, on the other hand, subretinal injec-
tion is clinically the most investigated technique, especially
for targeting photoreceptors or RPE cells in the outer retina.
We, and others, however, strongly believe IVT injection can
be a worthy alternative for gene delivery to the retina, espe-
cially when (widespread) expression over the inner retinal tis-
sue should be obtained (Da Costa et al., 2016; Ochakovski
et al., 2017). Yet, to ensure effective gene therapy after IVT
Figure 6. (A) Retinal cross-section of bovine retina with vitreous attached. Green: 100 nm polystyrene beads injected in the vitreous; Red: ILM stained for collagen,
which also stains retinal blood vessels (); Blue: Hoechst staining of nuclei. Scale bar 50 mm. (B) Representative cryosection images showing the transport of PS
beads through the vitreoretinal interface, 24 h after injecting the PS beads in the vitreous of the VR explant. ILM and blood vessels are stained by anti-collagen anti-
bodies (red), nuclei (blue) with Hoechst, particles are shown in green. Note that the contrast in the middle panel is enhanced to optimally visualize the PS beads,
while the brightness of the PS beads is reduced in the right panel to illustrate the perfect alignment of the vitreous and ILM. For optimal contrast we refer the
reader to the online version. The scale square in the top left image represents 1000 mm2 (31.6 mm 31.6mm). Scale bar: 31.6mm. (C) Semi-quantitative analysis of
transport of PS beads through the VR interface after 24 h incubation. (n¼ 3).
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injection, gene carriers have to pass the VR interface before
reaching the retina. Three parts of this VR interface can be
considered as a hurdle: peripheral vitreous, the ILM, and
M€uller cell endfeet (Figure 1). Strikingly, gene carriers often
efficiently overcome these hurdles in small animal in vivo
studies, usually on rodents, though this success is rarely
extrapolated to larger animal models like pigs (Trapani et al.,
2015). Based on our knowledge on interspecies differences in
ocular anatomy and barrier structure this does not entirely
come as a surprise: the combination of the smaller volume of
vitreous (5–20 ml) (Lebrun-Julien et al., 2009), its more liquid
composition and the reduced ILM thickness make the VR
interface in mice hardly representative for the human situ-
ation (Skeie & Mahajan, 2013). For this reason, several
research groups focus on the culture of large animal retinal
explants, however, this usually implies detachment of the vit-
reous gel so information on the VR interface is lost (Kobuch
et al., 2008; Fradot et al., 2011). We therefore aimed to bridge
the gap between these ex vivo models and the eventual in
vivo situation in large animals and humans, by developing a
novel ex vivo explant model based on bovine eyes that main-
tains the entire VR interface intact. We show that our VR
explant remains viable for at least two days and its morph-
ology is rather human-like (Figures 3 and 4). Furthermore, we
demonstrate that our model is ideally suited to study the
penetration of particles across the VR interface into the retina
after IVT injection.
Conveniently, our VR explant model allows for two ways
of imaging, where both ways have their merits. The direct
imaging method (Figure 2(B)) is faster, less labor-intensive
and requires for less tissue manipulation which results in
optimal integrity of the whole tissue. The observable tissue
depth is, however, limited to the ganglion cell layer. On the
other hand, cryosection preparation and imaging (Figure
2(C)) is rather labor-intensive but gives a full cross-section of
all retinal layers and allows to stain for a plethora of markers
by immunostaining.
We purposely opted for an ex vivo approach since this
comes with several advantages. Firstly, highly relevant drug
delivery studies can be performed on representative large
animal species such as pig, cow, or even human donor eyes;
this without the high costs that accompany the care and
housing of larger species as required for in vivo studies.
Secondly, ex vivo assays are convenient and accessible: eyes
can be easily obtained from local slaughterhouses, and only
basic cell culture and dissection materials are required to cul-
ture our VR model, making it feasible for every researcher.
Finally, the application of ex vivo assays is in line with the
worldwide aim to implement the 3 R principle (replacement,
reduction and refinement), originally introduced by Russell
and Burch as guidelines for more ethical and less use of
laboratory animals (Russell & Burch, 1959).
To demonstrate the value and functionality of our VR
explant for drug delivery, we looked into the size-dependent
transfer of NPs through the VR interface into the retina. We
decided to use commercially available carboxylated polystyr-
ene beads, since these particles are highly fluorescent, well
characterized and monodisperse as confirmed by our DLS
measurements (Table 1). Furthermore, these particles have
potential to penetrate into the retina after IVT injection as: 1)
the NP sizes are lower than the estimated mesh size of the
vitreal collagen network (550 nm) (Xu et al., 2013) 2) nega-
tively charged particles exhibit ideal vitreal mobility and do
not aggregate in the vitreous (Sakurai et al., 2001; Bejjani
et al., 2005; Kim et al., 2009; Xu et al., 2013; Martens et al.,
2015), and 3) in contrast to positively charged particles, nega-
tively charged ones have been reported before to cross the
ILM (Pitk€anen et al., 2004; Koo et al., 2012). As anticipated,
the PS beads did effectively enter the retina and more
importantly, a clear size-dependent trend was noticeable
using both imaging methods (Figures 5 and 6): 40 nm PS
beads more easily entered the retina from the vitreous than
100 and 200 nm sized beads. It is essential to note that for a
given particle size, the number of NPs that crossed the VR
interface varied greatly between different retinas and even
for different locations within the same retinal explant. For
this reason the retinal section data were presented as a dis-
tribution rather than only showing the most occurring
Figure 7. (A) Representative cryosection images showing the transport of 100 nm sized PS beads into the retina, 24 h after applying the beads on the explants. Top
row: no vitreous, bottom row: no ILM. ILM and blood vessels (red) are stained by anti-COLIV antibodies, nuclei (blue) with Hoechst, particles are shown in green.
Scale bar: 20 mm. (B) Semi-quantitative analysis of 100 nm PS bead uptake in vitreoretinal explants compared to conventional explants without vitreous (n¼ 3).
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observation. A potential explanation for this variety in uptake
within and between VR explants is that the ILM thickness
varies depending on the retinal region (Bu et al., 2015), as
well as on the age of the animal (Halfter et al., 2008;
Candiello et al., 2010). In addition, although the same particle
concentration and injection volumes were injected into the
vitreous of the various VR explants, the injection location and
the diffusion of particles from the injection spot eventually
determine the actual NP concentrations across the vitreous
and the retina.
Once NPs passed the VR interface, they were generally
located in the inner retinal layers, which is in line with the
rationale of exploring IVT injection as a valuable strategy for
gene therapy, primarily for targeting cell types in the inner
retina. Using the direct imaging method we further observed
that 40 nm particles co-localized specifically with M€uller cell
endfeet (Figure 5(B)), an observation also made by Koo et al.
with human serum albumin based nanoparticles in rats (Kim
et al., 2009; Koo et al., 2012). Since the M€uller cell endfeet
abut in the ILM, these cells are likely the first ones particles
encounter after IVT injection. Also our in vitro uptake studies
demonstrate that bovine primary M€uller cells efficiently endo-
cytose NPs (data not shown). Unfortunately, we were unable
to confirm a clear co-localisation of NPs and M€uller cells
using cryosection imaging.
Interestingly, while 100 nm sized particles had difficulty
crossing the VR interface in our hands, some reports discuss
the easy entry of larger particles into the retina (Bourges
et al., 2003; Kim et al., 2009; Koo et al., 2012; Apaolaza et al.,
2016). Koo et al. for example found 350 nm sized negatively
charged human serum albumin particles to easily enter the
retina in rats after IVT injection (Koo et al., 2012). Similarly,
neutral polylactide particles of the same size were reported
to accumulate at the ILM followed by smooth penetration
into the rat retina as well (Bourges et al., 2003). Also solid
lipid nanoparticles of 230 nm resulted in efficient transfection
across nearly all retinal layers after IVT injection in mice
(Apaolaza et al., 2016). It should be noted, however, that all
these observations were made in rodents, which could
account for the contrast with our data obtained in bovine
eyes.
To illustrate the importance of preserving the VR interface,
we have investigated the uptake of 100 nm sized NPs in con-
ventional explants without vitreous. At the same time, this
allows us to explore the specific barrier roles of the different
parts of the VR interface. Removing the vitreous had a posi-
tive effect on retinal uptake, since the fraction of explants
containing high amounts of NPs increased and larger NP
aggregates were able to enter the inner layers of the retina
(Figure 7(A,B)). Notably, the vitreous does not represent a
major barrier for these negatively charged 100 nm PS beads
since they are known to have good vitreal mobility (Martens
et al., 2013). We therefore expect the effect of vitreous
removal to be more pronounced for positively charged par-
ticles that are obstructed by their interaction with the nega-
tively charged components of the vitreous (Pitk€anen et al.,
2003; Peeters et al., 2005; Kim et al., 2009; Koo et al., 2012;
Martens et al., 2013; Xu et al., 2013), and for particles that
are larger than the mesh size of the vitreal network
(550 nm) (Xu et al., 2013). Next to losing information on the
barrier function of the vitreous for a particular NP, tearing off
the vitreous also influences the barrier function of the ILM. In
fact, Russell et al. found that vitreous separation commonly
results in ILM breaks, ILM evulsion and sporadically even loss
of inner retinal layers in cynomolgus monkeys (Russell, 2012).
An example of ILM separation upon vitreous removal can be
seen in Figure 7(A – ILM), a condition that clearly results in
massive NP uptake in the retina. A similar observation was
made by Gan et al. who witnessed enhanced penetration of
liponanoparticles through the disintegrated ILM of rats suffer-
ing from uveitis when compared to healthy rats (Gan et al.,
2013). Considering the spectacular contrast in retinal delivery
in a retina with and without the ILM, it is obvious that the
ILM is a crucial barrier for gene therapy. Seemingly, it func-
tions as a sieve that defines the type and number of particles
presented to the inner retinal cells.
The significant role of the vitreous and ILM as a barrier for
drug delivery and the influence of vitreous removal on the
integrity of both of them again highlights the necessity of
the model presented in this study. Certainly, our bovine-
derived VR explant could be highly valuable as a relevant
set-up to assess if promising particles, showing favorable in
vitro results, are competent in crossing the different hurdles
connected to the VR interface. However, despite its value,
some general remarks can be made. It should be noted that
by isolating the vitreous along with the retina, the vitreous
loses the natural support of the eyecup, causing a partial col-
lapse of the vitreal collagen network (Nickerson et al., 2008).
While potential (unwanted) interactions of particles with the
vitreal components will still be detected in our model, we
refer the reader to other advanced models, such as the one
developed by our research group, when exact diffusional
rates of fluorescent particles in intact vitreous are to be
determined (Martens et al., 2013). Secondly, while the VR
explant greatly mimics the in vivo situation, certain dynamic
processes present in the living eye are not taken into
account such as clearance mechanisms and the anterior-pos-
terior flow present in the vitreous (Xu et al., 2000). The cur-
rently available ex vivo system that most closely resembles
the in vivo situation, is the perfused eye model. In this
approach, an entire eye is isolated, cannulated and perfused,
keeping the eye globe perfectly intact (Mains et al., 2011,
2012). This eye integrity is highly beneficial, although it
comes with the disadvantage that these perfused eyes are
only viable for a limited time (9 hours). In contrast, our VR
explant remains viable for at least 2 days, making it more
suitable to evaluate retinal uptake of carriers after IVT injec-
tion. For long-term follow-up of gene carriers, however, in
vivo studies remain indispensable as for example retinal gene
expression usually only reveals itself after 2weeks (Mowat
et al., 2014; Wassmer et al., 2017).
5. Conclusions
For future research, we argue that further detailed character-
ization of the properties and composition of the vitreous and
ILM across species could help to identify which models are
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the most suited for IVT drug delivery studies with the retina
as main target. Thanks to the valuable research performed
on especially developed large animal models we have the
knowledge to smartly design vectors able of overcoming the
vitreous as a barrier. In contrast, owing to the diversity of
vectors studied on a variety of species the physicochemical
requirements to efficiently cross the ILM is way less coherent.
Well-designed systematic studies into which particle proper-
ties do result in successful retinal entry from the vitreous
could therefore form a sound foundation for future design of
‘the’ optimal gene carrier administered by IVT injection. We
are strongly convinced that advanced ex vivo models, such
as the one presented in this paper, could have great signifi-
cance in reaching this goal. Surely, our VR explant is currently
the most representative ex vivo model on the market that is
viable for a sufficiently long time to study carrier uptake.
Moreover, our ex vivo approach is readily accessible, relatively
cheap and transferrable to other large species like pig or
human.
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